Tarlatamab

Tarlatamab is a monoclonal antibody designed for the treatment of cancer. It is a type of immunotherapy that targets specific proteins on cancer cells to stimulate the body's immune system to attack the cancer.

Mechanism of Action

Tarlatamab works by binding to a specific protein found on the surface of cancer cells. This protein, known as CD38, is overexpressed in many types of cancer, including multiple myeloma and some leukemias. By binding to CD38, tarlatamab triggers an immune response that leads to the destruction of the cancer cells.

Clinical Trials

Tarlatamab has been studied in several clinical trials for its effectiveness in treating various types of cancer. These trials have shown promising results, with some patients experiencing significant reductions in tumor size and improved survival rates.

Side Effects

Like all drugs, tarlatamab can cause side effects. The most common side effects reported in clinical trials include fatigue, nausea, and fever. More serious side effects can include anemia, neutropenia, and thrombocytopenia.

Future Research

Research is ongoing to determine the full potential of tarlatamab in cancer treatment. This includes exploring its use in combination with other therapies, as well as investigating its effectiveness in treating other types of cancer.

See Also

• Monoclonal antibodies in cancer therapy
• Immunotherapy
• CD38
• Clinical trial

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian